# Cardiff Oncology

Cardiff Oncology is an Asset Manager based in San Diego, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** San Diego, United States
- **Region:** North America
- **Address:** San Diego, CA, United States
- **Founded:** 2013
- **Assets under management:** Undisclosed
- **Website:** cardiffoncology.com

## Regulatory record

- **Reports private funds:** No

## About

Cardiff Oncology incorporated in 2013 and went public through a reverse merger in 2020, placing it in a thin band of small-cap biotechs that carry a single-molecule research-and-development engine. Mark Erlander, a molecular biologist by training with prior leadership roles at bioTheranostics and a Merck KGaA legacy diagnostics unit, built the company around onvansertib, a Polo-like kinase 1 inhibitor that Cardiff licensed from Nerviano Medical Sciences. The wealth behind the firm is not a family fortune; it is venture and public-market capital raised to fund clinical trials. Cardiff's strategy is narrow and binary: advance onvansertib through a sequence of phase 2 investigator-sponsored and company-sponsored trials. The asset-class mix is effectively pure-play oncology clinical development, with stage coverage that spans phase 1b through pivotal phase 2 studies. The firm runs no diversified discovery platform, no preclinical library, and no revenue-stage products. Its pipeline is driven by biomarker-defined patient selection, most visibly in its lead program testing onvansertib combined with standard-of-care FOLFIRI and bevacizumab in KRAS-mutated metastatic colorectal cancer. No consummated partnerships with large pharmaceutical co-developers exist as of mid-2026, and the balance sheet, which reported $72.7 million in cash at end-of-year 2025 (per the firm's SEC filings, 2025), funds operations into 2027 without requiring a near-term dilutive raise. Cardiff Oncology operates from a single San Diego headquarters with a headcount below 30 full-time employees, typical for a clinical-stage biotech of its market-cap profile. No affiliated family-office vehicles, philanthropic foundations, or real-asset arms are tied to the corporate entity. The firm is not known to participate in pooled fund structures, syndicated co-investment vehicles, or Tiger 21 / R360 membership networks. The operating model is unusual in that the core molecule is not a novel chemical entity invented in-house; it is a repositioned compound combined with standard-of-care comparator arms that the academic cooperative groups and the FDA already know well. Succession and governance are straightforward — Erlander remains the scientific and strategic anchor, and the board operates as a conventional public-company oversight body.

## Sectors

- Healthcare Services

## People

- Mark Erlander — Chief Executive Officer

## Questions

### What is Cardiff Oncology's lead drug candidate, and what makes its approach distinct?

The lead candidate is onvansertib, a Polo-like kinase 1 inhibitor that Cardiff is repurposing from a generic oncology backbone into a biomarker-guided therapy. The firm's approach targets KRAS-mutated metastatic colorectal cancer — a genetic subgroup that historically responds poorly to standard chemotherapy — by combining onvansertib with FOLFIRI and bevacizumab. The differentiation lies in using a randomized trial design to test a repositioned molecule against a precisely defined mutation-driven population, rather than running open-label single-arm studies (per clinical trial protocols disclosed on ClinicalTrials.gov).

### How does Cardiff Oncology fund its clinical programs?

Cardiff Oncology funds its operations through equity offerings registered with the SEC and, to a lesser extent, warrant exercises. The company reported $72.7 million in cash, cash equivalents, and short-term investments as of December 31, 2025, projecting a runway into 2027 (per the firm's annual SEC filings, 2025). No pharmaceutical partnership revenue or licensing fees currently support the balance sheet.

### Does Cardiff Oncology have any large pharmaceutical partners?

No. As of mid-2026, Cardiff Oncology has not announced a co-development agreement, licensing deal, or equity investment from a major pharmaceutical company. The firm retains full global rights to onvansertib, a structure that increases potential upside but also concentrates development risk on a single balance sheet.

### How is Cardiff Oncology governed and who holds executive decision-making authority?

Mark Erlander serves as CEO and anchors scientific and strategic direction. The board operates as a conventional public-company governance body with audit, compensation, and nominating committees. No dual-class share structure or super-voting founder rights have been disclosed in SEC filings, placing control firmly under standard independent-board oversight.

### What is the firm's relationship to its original asset licensor, Nerviano Medical Sciences?

Cardiff Oncology licensed onvansertib from Nerviano Medical Sciences, an Italian oncology research company. The licensing agreement predates Cardiff's public listing and is disclosed in SEC filings as a material contract. Cardiff is the active clinical sponsor and bears full development and regulatory costs; Nerviano is entitled to milestone payments and royalties upon approval.

## Related profiles

- [Nano-X Imaging](https://altss.com/profile/nano-x-imaging-ltd)
- [Nuveen Massachusetts Quality Municipal Income Fund](https://altss.com/profile/nuveen-massachusetts-quality-municipal-income-fund)

---

Last updated: 2026-08-11T02:43:31.692Z

Canonical page: https://altss.com/profile/cardiff-oncology-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology